ABL Texcell Diagnostics SA (EPA:ABLD)
France · Delayed Price · Currency is EUR 2.360
-0.020 (-0.84%)
Oct 23, 2026, 9:05 AM CEST
ABL Texcell Diagnostics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 11.13 | 7.97 | 5.87 | 6.19 | 9.36 | - |
Other Revenue | -0 | -0 | - | -0 | -0 | - |
| 11.13 | 7.97 | 5.87 | 6.19 | 9.36 | - | |
Revenue Growth | 78.60% | 35.71% | -5.16% | -33.89% | 936127200.00% | - |
Cost of Revenue | 7.55 | 5.56 | 4.32 | 5.07 | 6.27 | 0.1 |
Gross Profit | 3.58 | 2.4 | 1.55 | 1.12 | 3.09 | -0.1 |
Selling, General & Admin | 1.69 | 1.5 | 1.5 | 1.46 | 1.33 | - |
Other Operating Expenses | -0.05 | -0.02 | -0.2 | -0.35 | 1.14 | 0 |
Operating Expenses | 2.09 | 2.08 | 2.04 | 1.77 | 3.04 | 0 |
Operating Income | 1.5 | 0.32 | -0.49 | -0.66 | 0.06 | -0.1 |
Interest Expense | -0.08 | -0.07 | -0.07 | -0.05 | -0.01 | - |
Interest & Investment Income | 0.07 | 0.07 | 0.04 | 0.04 | 0.03 | 0 |
Currency Exchange Gain (Loss) | -0 | -0.01 | 0 | -0 | -0 | - |
Other Non Operating Income (Expenses) | 0 | 0 | 0.02 | -0 | 0 | -0 |
EBT Excluding Unusual Items | 1.48 | 0.31 | -0.5 | -0.67 | 0.08 | -0.1 |
Gain (Loss) on Sale of Investments | -0.01 | 0.05 | -0 | - | - | - |
Gain (Loss) on Sale of Assets | -0.03 | -0.03 | - | 0.05 | 0.42 | -0 |
Other Unusual Items | - | - | 0.06 | -0 | -0 | 0.4 |
Pretax Income | 1.44 | 0.33 | -0.44 | -0.62 | 0.49 | 0.3 |
Income Tax Expense | -0.54 | -0.66 | -0.72 | -0.68 | -0.62 | 0.04 |
Net Income | 1.98 | 0.99 | 0.29 | 0.05 | 1.11 | 0.26 |
Net Income to Common | 1.98 | 0.99 | 0.29 | 0.05 | 1.11 | 0.26 |
Net Income Growth | 326.81% | 246.00% | 424.58% | -95.08% | 328.78% | - |
Shares Outstanding (Basic) | - | 16 | 14 | 16 | 16 | 2 |
Shares Outstanding (Diluted) | - | 16 | 14 | 16 | 16 | 2 |
Shares Change | - | 15.33% | -11.51% | 2.02% | 687.22% | - |
EPS (Basic) | - | 0.06 | 0.02 | 0.00 | 0.07 | 0.13 |
EPS (Diluted) | - | 0.06 | 0.02 | 0.00 | 0.07 | 0.13 |
EPS Growth | - | 200.00% | 492.94% | -95.18% | -45.53% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1.76 | 0.71 | -2.32 | - | - | -0.06 |
Free Cash Flow Per Share | - | 0.04 | -0.16 | - | - | -0.03 |
Dividend Per Share | 0.110 | 0.110 | 0.050 | - | - | - |
Dividend Growth | 120.00% | 120.00% | - | - | - | - |
Gross Margin | 32.20% | 30.15% | 26.34% | 18.05% | 33.06% | - |
Operating Margin | 13.46% | 3.98% | -8.36% | -10.62% | 0.63% | - |
Profit Margin | 17.77% | 12.39% | 4.86% | 0.88% | 11.81% | - |
Free Cash Flow Margin | 15.82% | 8.97% | -39.45% | - | - | - |
EBITDA | 1.3 | 0.43 | 0.27 | 0.01 | 0.62 | - |
EBITDA Margin | 11.70% | 5.38% | 4.55% | 0.08% | 6.62% | - |
D&A For EBITDA | -0.2 | 0.11 | 0.76 | 0.66 | 0.56 | - |
EBIT | 1.5 | 0.32 | -0.49 | -0.66 | 0.06 | -0.1 |
EBIT Margin | 13.46% | 3.98% | -8.36% | -10.62% | 0.63% | - |
Effective Tax Rate | - | - | - | - | - | 12.87% |
Revenue as Reported | 11.39 | 8.22 | 6.22 | 7.69 | 9.39 | 0 |